Key Documents

View All Documentation

Y0000408

Stavudine

Name: Stavudine
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2′,3′-Didehydro-3′-deoxythymidine, 1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine, 1-[(2R,5S)-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-(1H,3H)-dione, 2′,3′-Anhydrothymidine, Stavudine, d4T

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₀H₁₂N₂O₄

CAS Number:

3056-17-5

Molecular Weight:

224.21

NACRES:

NA.24

PubChem Substance ID:

329830940

UNSPSC Code:

41116107

MDL number:

MFCD00132921

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

stavudine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

InChI

1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

InChI key

XNKLLVCARDGLGL-JGVFFNPUSA-N

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Stavudine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under Stavudine

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides.

John C Martin et al.

Antiviral research, 85(1), 34-38 (2009-10-27)

The occasion of this 25th anniversary issue encouraged us to reminisce about the important history of the discovery of the dideoxynucleoside analogues for the treatment of HIV/AIDS and to chronicle our thoughts about a particular exciting and rewarding period of

Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings.

Alain Makinson et al.

Expert opinion on drug safety, 7(3), 283-293 (2008-05-09)

Western randomized trials and prospective cohorts in resource-limited settings have proven virological success with stavudine-based highly active antiretroviral therapy. However, stavudine is no longer recommended in first-line treatments in these two settings due to its intrinsic toxicities and side effects.

Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.

N Clumeck

Antiviral therapy, 3 Suppl 4, 39-43 (2000-03-21)

Current guidelines for treatment of human immunodeficiency virus (HIV) disease favour the use of triple-drug combinations consisting of two nucleoside analogue reverse transcriptase inhibitors (NRTIs) plus a protease inhibitor to achieve maximum suppression of HIV replication. There is considerable evidence

View All Related Papers

Global Trade Item Number

SKU	GTIN
Y0000408	04061833795026